ライフサイエンスコーパス: hypersecretion

1 ultures with induced mucous metaplasia/mucin hypersecretion.

2 oblet cell hyperplasia/metaplasia, and mucus hypersecretion.

3 ter B cells and plasma cells as well as IgG1 hypersecretion.

4 esponsiveness (AHR), inflammation, and mucus hypersecretion.

5 ciated with goblet cell metaplasia and mucus hypersecretion.

6 functional K(ATP) channels leads to insulin hypersecretion.

7 striction, parenchymal destruction and mucus hypersecretion.

8 lications for the management of airway mucus hypersecretion.

9 matory airway diseases associated with mucus hypersecretion.

10 ons, which are associated with further mucus hypersecretion.

11 nic factors predominated in sinusitis mucous hypersecretion.

12 pharmacological intervention to treat mucus hypersecretion.

13 local invasion, hypopituitarism, or hormone hypersecretion.

14 uid and airway tissue eosinophilia and mucus hypersecretion.

15 targeted specifically for therapy of airway hypersecretion.

16 l infiltration, VCAM-1 expression, and mucus hypersecretion.

17 rising from pituitary intermediate lobe ACTH hypersecretion.

18 B(4) may play a major role in allergic nasal hypersecretion.

19 ain fatty acids replicates the basal insulin hypersecretion.

20 tty acids (FAs) replicates the basal insulin hypersecretion.

21 ttenuated, thereby causing the basal insulin hypersecretion.

22 ors require endocrine evaluation for hormone hypersecretion.

23 ation, airway hyperresponsiveness, and mucus hypersecretion.

24 astrointestinal symptoms due to rebound acid hypersecretion.

25 airway constriction, inflammation, and mucus hypersecretion.

26 H and PHH by antagonizing SPAK-dependent CSF hypersecretion.

27 formation, cellular inflammation, and mucus hypersecretion.

28 species (ROS) production, NETosis, and mucus hypersecretion.

29 ides an enlarged pituitary contribute to the hypersecretion.

30 ng in increased airway eosinophils and mucus hypersecretion.

31 s were airway hyperresponsiveness and mucous hypersecretion.

32 sequence of rapid glucose appearance and GIP hypersecretion.

33 nt of diseases that rely on SNAP-23-mediated hypersecretion.

34 and increases viral titres, leading to mucus hypersecretion.

35 volves airway hyper-responsiveness and mucus hypersecretion.

36 competent CTLs/NK cells and caused cytokine hypersecretion.

37 D of p53 as a determinant for chronic mucous hypersecretion.

38 or after prolonged exposure induces insulin hypersecretion.

39 he severity of airway inflammation and mucus hypersecretion.

40 etermined by gland size (10%) versus hormone hypersecretion (3%) was statistically different (P < 0.0

41 lnerable to stress and less adaptable to CRF hypersecretion, a condition found in patients with PTSD

42 ficiencies (B12 and magnesium), rebound acid hypersecretion, acute interstitial nephritis, gastric ca

43 A detailed mucus hypersecretion adverse outcome pathway (AOP) has been co

44 or NU7441 reduced airway eosinophilia, mucus hypersecretion, airway hyperresponsiveness, and OVA-spec

45 ld-type mice had chronic inflammation, mucus hypersecretion, airway remodeling, emphysema, and reduce

46 notype in Muc5ac-Tg mice suggests that mucin hypersecretion alone is not sufficient to trigger lumina

47 FD in C57BL/6NTac mice entails early insulin hypersecretion and a robust growth phase along with hype

48 Effective control of GH and IGF1 hypersecretion and ablation or stabilization of the pitu

49 disease characterized by inflammation, mucus hypersecretion and abnormal airway smooth muscle (ASM) c

50 s result in dysregulated growth hormone (GH) hypersecretion and acromegaly; however, regulatory mecha

51 eated Hyp-mice displayed ameliorated mucosal hypersecretion and airway hyper-responsiveness.

52 ic airway inflammation, which leads to mucus hypersecretion and airway hyperresponsiveness.

53 Local allergen challenge causes nasal hypersecretion and also causes local leukotriene (LT) re

54 ituted the goblet cell hyperplasia, cytokine hypersecretion and decreased ciliary function of asthmat

55 Hypersecretion and depletion of mucin-2 (MUC2) mucin fro

56 -13, airway hyperresponsiveness (AHR), mucus hypersecretion and eosinophilia.

57 Remodeling processes, such as mucus hypersecretion and extracellular matrix protein producti

58 lular functions such as proliferation, mucus hypersecretion and fibroblast differentiation in inflame

59 nts revealed changes consistent with insulin hypersecretion and glucose sensing failure, which were c

60 to enhanced beta-cell excitability, insulin hypersecretion and hypoglycaemia, and in humans lead to

61 models of depression, namely stress hormone hypersecretion and increased passive coping behavior, su

62 sessed by airway hyper-responsiveness, mucus hypersecretion and inflammatory cell recruitment.

63 tress responses and allow for glucocorticoid hypersecretion and its attendant pathophysiology.

64 that Lyn overexpression decreased the mucus hypersecretion and levels of the muc5ac transcript in mi

65 of the airways that is associated with mucus hypersecretion and obstruction of small airways.

66 Mucus hypersecretion and persistent airway inflammation are co

67 Ac-1-phosphotransferase results in hydrolase hypersecretion and profound lysosomal storage.

68 ficient animals specifically inhibited mucus hypersecretion and reduced IL-13.

69 All had controlled acid hypersecretion and were assessed yearly, with a mean fol

70 ltration, goblet cell hyperplasia with mucus hypersecretion, and accumulation and activation of intra

71 ity, eosinophilic airway inflammation, mucus hypersecretion, and Ag-specific Ig production.

72 ic inflammation, Th2 cytokine release, mucus hypersecretion, and AHR.

73 ion in airway eosinophil infiltration, mucus hypersecretion, and airway hyperreactivity in response t

74 atures of asthma: airway eosinophilia, mucus hypersecretion, and airway hyperreactivity.

75 cterized by eosinophilic inflammation, mucus hypersecretion, and airway hyperresponsiveness (AHR).

76 that is characterized by inflammation, mucus hypersecretion, and airway hyperresponsiveness.

77 hyperresponsiveness, gene expression, mucus hypersecretion, and airway inflammation was assessed by

78 However, goblet cell metaplasia, mucus hypersecretion, and airway obstruction are integral feat

79 including on airway epithelial cells, mucus hypersecretion, and airway remodelling, and consequently

80 g antibody attenuated ILC2 expansion, mucous hypersecretion, and airways responsiveness.

81 ling, extracellular matrix production, mucus hypersecretion, and eosinophil activation.

82 l and microbial agents causing inflammation, hypersecretion, and epithelial necrosis.

83 reduced airway hyperreactivity (AHR), mucus hypersecretion, and fibrosis.

84 st scores, frequent history of chronic mucus hypersecretion, and frequent use of oral corticosteroids

85 cell maturation phenotypes, including IL-12 hypersecretion, and higher major histocompatibility comp

86 allergen-induced airway inflammation, mucus hypersecretion, and hyperresponsiveness in the hGX-sPLA(

87 ated with a reduction in eosinophilia, mucus hypersecretion, and IL-5 and IL-13 production upon the a

88 While inflammation, fibrosis, mucus hypersecretion, and metaplastic epithelial lesions are h

89 vate ILC2s, resulting in eosinophilia, mucus hypersecretion, and remodeling of mucosal tissues.

90 mmatory cell infiltrate and mediators, mucus hypersecretion, and serum total IgE.

91 a therapeutic target for inflammation, mucus hypersecretion, and structural lung damage and indicate

92 ovalbumin-induced airway eosinophilia, mucus hypersecretion, and Th2 cytokine production (IL-4/IL-5/I

93 g to eosinophilic airway inflammation, mucus hypersecretion, and Th2 cytokine production in response

94 velopment of AHR, airway eosinophilia, mucus hypersecretion, and TH2 cytokine production without chan

95 ized by airway epithelial cell damage, mucus hypersecretion, and Th2 cytokine production.

96 Eosinophil recruitment and mucus hypersecretion are characteristic of asthmatic airway in

97 n leading to airflow obstruction, and mucous hypersecretion are clinical hallmarks of asthma.

98 Goblet cell metaplasia and mucus hypersecretion are important features in the pathogenesi

99 Chronic inflammation and mucus hypersecretion are key features of COPD.

100 r, the signalling pathways regulating MUC5AC hypersecretion are not fully characterised.

101 Calcium bursts and hypersecretion are reversed by mutations in the ryanodin

102 agent would have therapeutic value for mucus hypersecretion as it is the major cause of airway obstru

103 ced inflammatory cell infiltration and mucus hypersecretion as observed in lung sections, and mRNA ex

104 es a molecular basis for biliary cholesterol hypersecretion as the mechanism for cholesterol gallston

105 values underestimate the degree of hydrolase hypersecretion as these enzymes were rapidly cleared fro

106 ere examined for cell infiltration and mucus hypersecretion, as well as the expression of antioxidant

107 rway diseases associated with chronic mucous hypersecretion.Bcl-2 interacting killer (Bik) decreases

108 FDRs to maintain their compensatory insulin hypersecretion beyond 18 h of hyperglycemia.

109 so diminished goblet cell hyperplasia, mucus hypersecretion, bronchoalveolar lavage eosinophilia, alt

110 gen-induced airway hyperreactivity and mucus hypersecretion but not for fibroblast or alternative mac

111 However, IL-6 is essential for mucus hypersecretion by airway epithelial cells triggered in r

112 ity that adenosine also contributes to mucus hypersecretion by airway epithelial cells.

113 Lyn overexpression ameliorated airway mucus hypersecretion by down-regulating STAT6 and its binding

114 ated that M. pneumoniae induces airway mucus hypersecretion by modulating the STAT/EGFR-FOXA2 signali

115 IL-1beta hypersecretion by monocytes involves decreased mitochond

116 The mechanism of gastric acid hypersecretion by NGASP was investigated in rats.

117 ho-A/Rho kinase inhibitor, affects the mucus hypersecretion by suppressing MUC5AC via signal transduc

118 chanism by which M. pneumoniae induces mucus hypersecretion by using M. pneumoniae infection of mouse

119 beta-cell excitability: the expected initial hypersecretion can progress to undersecretion and glucos

120 Chronic mucus hypersecretion (CMH) is common among smokers and is asso

121 ogy of iMCD-TAFRO and the basis for cytokine hypersecretion commonly seen in iMCD-TAFRO patients has

122 s minimally perturbed, demonstrating insulin hypersecretion compensated for insulin resistance.

123 f further medical conditions associated with hypersecretion components is prevented partly because th

124 Goblet cell hyperplasia and mucous hypersecretion contribute to the pathogenesis of chronic

125 ersion to CSCs via MEC co-culture (e.g., MMP hypersecretion, decreased PTEN).

126 therapeutic potential for treatment of human hypersecretion diseases.

127 subjects showed higher glycemia and insulin hypersecretion due to greater beta-cell glucose and rate

128 partakes in biliary phosphatidylcholine (PC) hypersecretion during cholesterol cholelithogenesis.

129 secretion in type 1 diabetes (T1D) involves hypersecretion during postprandial states, but insuffici

130 educed airway eosinophil infiltration, mucus hypersecretion, edema, and IL-4 levels in a mouse asthma

131 rway hyperreactivity, T(H)2 responses, mucus hypersecretion, eosinophil infiltration, and collagen de

132 ted airway hyperresponsiveness, glycoprotein hypersecretion, eosinophilia, and lung IL-4 responses.

133 ers of disease, including choroid plexus CSF hypersecretion, ependymal denudation, and damage and sca

134 usion criteria included evidence of lacrimal hypersecretion, eyelid malposition, and punctal or canal

135 ronchoalveolar lavage eosinophilia and mucus hypersecretion following the secondary challenge protoco

136 pheral blood insulin levels, despite insulin hypersecretion from pancreatic beta cells.

137 Glucagon hypersecretion from pancreatic islet alpha-cells exacerb

138 d-type enteropathogenic Escherichia coli and hypersecretion from sepL and sepD mutants.

139 filtration with concomitant epithelial mucus hypersecretion, goblet cell metaplasia, subepithelial fi

140 While the etiology is not well understood, hypersecretion has been linked to the presence of cytoki

141 trin-releasing peptide that could cause acid hypersecretion; however, Zollinger-Ellison syndrome (ZES

142 stasis, such as choroid plexus-dependent CSF hypersecretion, impaired cilia-mediated CSF flow current

143 plexus and reduces cerebrospinal fluid (CSF) hypersecretion in a model of post-hemorrhagic hydrocepha

144 s and reverses pathological effects of mucus hypersecretion in a mouse allergic asthma model.

145 diated goblet cell differentiation and mucus hypersecretion in a murine model of allergic lung diseas

146 ver, its function in modulating airway mucus hypersecretion in asthma remains undefined.

147 ecretory drugs for treatment of airway mucus hypersecretion in asthma.

148 licate NKCC1 in the pathophysiology of mucus hypersecretion in asthma.

149 ell hyperplasia may lead to sustained mucous hypersecretion in chronic diseases.

150 Parenteral control of gastric acid hypersecretion in conditions such as Zollinger-Ellison s

151 function, and thereby reverse glucocorticoid hypersecretion in depression.

152 Although insulin hypersecretion in early stages has been implicated in be

153 y inflammation and hyperreactivity and mucus hypersecretion in house dust mite-challenged mice.

154 184 or PF-3845 blocked naloxone-precipitated hypersecretion in morphine-dependent small intestinal ti

155 ed to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data o

156 Medical control of acid hypersecretion in patients with sporadic ZES is highly e

157 that propofol (Diprivan) may stimulate mucus hypersecretion in patients without pulmonary disease.

158 there was no goblet cell metaplasia or mucus hypersecretion in response to OVA, even in the presence

159 t cell hyperplasia and metaplasia, and mucus hypersecretion in the airways.

160 okine production in the peritoneum, or mucus hypersecretion in the gastrointestinal tract.

161 diators of the eosinophilic influx and mucus hypersecretion in the lungs in a murine model of asthma.

162 minished eosinophilic inflammation and mucus hypersecretion in the lungs of allergen-sensitized and a

163 UC5AC production and IL-1beta-induced Muc5ac hypersecretion in tracheas from wild-type but not from C

164 in may potentiate each other to produce acid hypersecretion in ulcerogenic pancreatic tumor syndrome.

165 g-chain omega-3 fatty acids reversed insulin hypersecretion in vivo, and the effect of long-term high

166 In a cohort of patients with gastric acid hypersecretion in whom acid secretion status was monitor

167 es of the disease such as selective cytokine hypersecretion, increased neutrophil recruitment and cli

168 AT(1) receptor blocker, losartan, inhibited hypersecretion induced by C. difficile toxin A (mean vol

169 Previously, we reported that mucin hypersecretion induced by human neutrophil elastase invo

170 y abnormalities of COPD/CF, including mucous hypersecretion, inflammatory and emphysematous phenotype

171 glucose but results in compensatory glucagon hypersecretion involving expansion of pancreatic alpha-c

172 Mucus hypersecretion is a common characteristic of asthma.

173 Airway mucus hypersecretion is a feature of many patients with asthma

174 Mucus hypersecretion is a hallmark of asthma that contributes

175 Airway mucus hypersecretion is a key pathophysiologic feature in a nu

176 Airway mucus hypersecretion is a key pathophysiological feature in as

177 Mucous hypersecretion is a major cause of airway obstruction in

178 Mucin hypersecretion is a major pathological feature of many r

179 wever, it is unclear whether fasting insulin hypersecretion is a primary driver of insulin resistance

180 Mucus hypersecretion is a prominent manifestation in patients

181 Mucus hypersecretion is a prominent manifestation in patients

182 Airway hypersecretion is a serious and presently untreatable sy

183 Mucous hypersecretion is an important feature of obstructive ai

184 inemia causes insulin resistance and insulin hypersecretion is an independent risk factor for develop

185 Because mucus hypersecretion is common in purulent rhinitis, we questi

186 on syndrome (ZES) or idiopathic gastric acid hypersecretion is necessary perioperatively or when oral

187 Cortisol hypersecretion is one of the most reliable biological ab

188 y, not only because medical therapy for acid hypersecretion is so effective, but also in large part b

189 ther, these results indicate that adenoma GH hypersecretion is the result of STAT3-dependent GH induc

190 Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting pitui

191 ystem hyperreactivity, presumably due to CRF hypersecretion, is a persistent consequence of childhood

192 nt of insulin resistance, defined as primary hypersecretion, is associated with obesity and an unfavo

193 pogenesis, induced in hepatocytes by insulin hypersecretion, is followed by beta-cell destruction in

194 ts such as epithelial desquamation and mucus hypersecretion leading to airway obstruction, subepithel

195 included downregulation of pathways of mucus hypersecretion, leukocyte migration/activation, and endo

196 Consequently, mucin hypersecretion likely produces mucus stasis, which contr

197 xes, as displayed by humoral response, mucus hypersecretion, lung inflammatory cell infiltration and

198 ge, inflammatory cell recruitment, and mucus hypersecretion may be associated with substantial argina

199 understanding of the role of FOXA2 in mucus hypersecretion may lead to novel therapeutics against ex

200 d by loss-of-function mutations) and hormone hypersecretion (McCune-Albright syndrome caused by gain-

201 did not cause a comparable decrease in mucus hypersecretion, Muc 5ac gene expression, or the level of

202 rves to decrease airway resistance and mucus hypersecretion.Objectives: To determine the safety and i

203 ences of hypergastrinemia, including rebound hypersecretion of acid, and possible development of vari

204 receptors on the MMP-1 promoter and leads to hypersecretion of active MMP-1 enzyme and degradation of

205 on by CLA of MEK/ERK signaling was linked to hypersecretion of adipocytokines interleukin-6 and inter

206 Hypersecretion of airway mucin characterizes numerous re

207 Hypersecretion of amylin is common in individuals with p

208 Hypersecretion of basal cortisol, in conjunction with bl

209 eases in bile salt hydrophobicity and not to hypersecretion of biliary cholesterol per se, such as oc

210 ation normalized bile salt reabsorption, and hypersecretion of bilirubin was abolished.

211 lly associated with systemic symptoms due to hypersecretion of biogenic amines from metastatic lesion

212 nhibited by overnutrition, inflammation, and hypersecretion of certain anabolic hormones, such as ins

213 t diarrheal illnesses mediated by intestinal hypersecretion of chloride.

214 pituitary-adrenal axis activity secondary to hypersecretion of corticotropin-releasing hormone.

215 Hypersecretion of cortisol can be detected in asymptomat

216 Although hypersecretion of cortisol has frequently been reported

217 In this form of hyperplasia, hypersecretion of cortisol suppresses the release of cor

218 IVH-induced hypersecretion of CSF is mediated by TLR4-dependent acti

219 Hypersecretion of cytokines by innate immune cells is th

220 activation of the response regulator RegX3, hypersecretion of ESX-5 substrates and attenuation in th

221 n addition, we hypothesized that concomitant hypersecretion of glucagon and insulin was also contribu

222 Hypersecretion of glucagon from pancreatic alpha-cells s

223 is due to alpha-cell hyperplasia with gross hypersecretion of glucagon, which according to recent gr

224 aracrine mechanisms is believed to cause the hypersecretion of glucagon.

225 and the etiology is primarily thought to be hypersecretion of glucagon.

226 cagon maturation, lead to reduced alpha-cell hypersecretion of glucagon.

227 r depression, which is often associated with hypersecretion of glucocorticoids; and (3) posttraumatic

228 megaly is a rare endocrine disease caused by hypersecretion of growth hormone, most commonly arising

229 e AIP gene and are sometimes associated with hypersecretion of growth hormone.

230 pletion of STX10 leads to MPR missorting and hypersecretion of hexosaminidase.

231 T helper 1 cells show slight but significant hypersecretion of IFN-gamma in Grail(-/-) mice whereas T

232 We find that hypersecretion of IL-1beta and IL-18 requires reactive o

233 ammasome activation, thereby contributing to hypersecretion of IL-1beta in mevalonate kinase deficien

234 and their targets in real time, we show that hypersecretion of IL-2, TNF, IFN-gamma, and various chem

235 oxin, at sub nM concentrations, can suppress hypersecretion of IL-8 from cultured CF lung epithelial

236 lymphoplasmacytic lymphoma characterized by hypersecretion of immunoglobulin M (IgM) protein and tum

237 mmatory phenotype in HRMPs, characterized by hypersecretion of inflammatory and angiogenic mediators.

238 were identified as having MHSs involving the hypersecretion of insulin (5 patients), vasoactive intes

239 TP) channels in transgenic (AAA) mice causes hypersecretion of insulin and enhanced glucose tolerance

240 By 12 weeks of age, hypersecretion of insulin at 5.0 mmol/l glucose was obse

241 r of childhood associated with inappropriate hypersecretion of insulin by the pancreas.

242 ls leads to fasting-induced hypoglycemia and hypersecretion of insulin during GSIS.

243 athways do not contribute to the early-onset hypersecretion of insulin from islets of ob/ob mice.

244 Hypersecretion of insulin from the pancreas is among the

245 This inappropriate hypersecretion of insulin in the face of profound hypogl

246 The hypersecretion of insulin may be explained by a loss of

247 to obesity-associated insulin resistance is hypersecretion of insulin.

248 KC signaling system within islets to prevent hypersecretion of insulin.

249 tory pathway in pancreatic islets to prevent hypersecretion of insulin.

250 This phenotype was characterized by hypersecretion of interferon (IFN)-gamma and interleukin

251 activated chloride secretion, and suppresses hypersecretion of interleukin-8 (IL-8).

252 suggest that, in addition to activation and hypersecretion of matrix components, fibroblasts from pa

253 f MECs and NSCs rapidly (</= 3 weeks) caused hypersecretion of MMPs and marked suppression of the tum

254 CB is caused by overproduction and hypersecretion of mucus by goblet cells, which leads to

255 Hypersecretion of mucus is an important component of air

256 ration with decreased transport velocity and hypersecretion of mucus.

257 Significant hypersecretion of nitric oxide (NO) was observed in thio

258 h could account for the previously described hypersecretion of procathepsin D induced by wortmannin.

259 Dexamethasone at various potencies blocked hypersecretion of several proteins.

260 mutation of the RegX3 binding site reversed hypersecretion of the ESX-5 substrate EsxN by the Deltap

261 As hypersecretion of the stress neuromediator, corticotropi

262 The likely underlying mechanism is hypersecretion of vascular endothelial growth factor sec

263 Importantly, the hypersecretion of VLDL-TG from the liver induced by a mo

264 Finally, DVC glycine normalized the hypersecretion of VLDL-TG induced by high-fat feeding.

265 Yersinia-containing vacuoles (YCVs) requires hypersecretion of Yersinia translocon proteins.

266 Cushing's syndrome is a disease of cortisol hypersecretion often caused by mutations in protein kina

267 Airway inflammation and mucus hypersecretion/overproduction/obstruction are pathophysi

268 ncy state may be involved in the actual ACTH hypersecretion phenomenon.

269 ) mice displayed a cell-autonomous IL-1alpha hypersecretion phenotype, whereas T cells showed propens

270 tudies of the mechanisms responsible for the hypersecretion produced by cholera toxin (CT) have shown

271 al mechanism supporting compensatory insulin hypersecretion rather than exacerbating metabolic diseas

272 tumors (PNETs) may evolve and cause hormonal hypersecretion-related symptoms that were not present at

273 wever, regulatory mechanisms that promote GH hypersecretion remain elusive.

274 adenomas (FPAs) are associated with hormonal hypersecretion resulting in systemic endocrinopathies an

275 h includes recruitment of eosinophils, mucus hypersecretion, Th2 cytokine production, and airways hyp

276 al. show, in a mouse model of chronic mucous hypersecretion, that ciliated epithelial cell apoptosis

277 ation, airway hyperresponsiveness, and mucus hypersecretion to a similar degree as detected in mast c

278 duce DNA damage, potentially linking hormone hypersecretion to SCNA and genome instability.

279 responsiveness, lung inflammation, and mucus hypersecretion to the degree observed in wild-type mice.

280 previously unrecognized contribution of CSF hypersecretion to the pathogenesis of PHH, demonstrate a

281 Intriguingly, the CHI progression from hypersecretion to undersecretion actually mirrors the cl

282 ocytes, eosinophils, IL-13, IL-5, and mucous hypersecretion to wild-type levels, whereas eotaxin and

283 Mucus hypersecretion upon Pofut1 inactivation is accompanied b

284 investigated the role of PKC delta in mucin hypersecretion using both primary human bronchial epithe

285 thways that underlie MKD-associated IL-1beta hypersecretion using human cell cultures, Rac1 and RhoA

286 ined the hypothesis that LTB(4) causes nasal hypersecretion via neutrophil elastase.

287 Cholera toxin induces hypersecretion via release of mucosal serotonin and over

288 s signaling cascade is relevant to asthmatic hypersecretion was indicated by results showing that muc

289 Melatonin hypersecretion was observed in patients exposed to catec

290 nnervation, the authors discovered that GABA hypersecretion was required for the induction of mucin M

291 -12-myristate-13-acetate (PMA)-induced mucin hypersecretion was significantly attenuated by rottlerin

292 ivation/inflammation, high SNS tone, and CRH hypersecretion, which are all consistent with insufficie

293 zed by airway eosinophilia, as well as mucus hypersecretion, which can lead to airflow obstruction.

294 hopefully lead to novel therapies for mucin hypersecretion, which is an important cause of morbidity

295 Whether amelioration of basal insulin hypersecretion will prevent diabetes remains to be eluci

296 ic inflammation, an immune response, and IgA hypersecretion with an osmotic effect, all contributing

297 ive hormones and relieve symptoms of hormone hypersecretion with functional NETs.

298 flammation, Th2 cell accumulation, and mucus hypersecretion with mucus metaplasia.

299 hypertrophy and hyperplasia as well as mucus hypersecretion with subsequent airflow obstruction.

300 ppressed AHR, airway eosinophilia, and mucus hypersecretion without any reduction in TH2 cytokine pro